Alnylam review turns up no clear answers on revusiran deaths Submitted by admin on Thu, 08/10/2017 - 18:53 Read more about Alnylam review turns up no clear answers on revusiran deaths Source BioPharma Dive Headline Alnylam review turns up no clear answers on revusiran deaths News Tags Alnylam revusiran RNAi
7 of the Most Shocking Biotech Pipeline Blowups of 2016 Submitted by admin on Sun, 12/04/2016 - 12:37 Read more about 7 of the Most Shocking Biotech Pipeline Blowups of 2016 Source Motley Fool Headline 7 of the Most Shocking Biotech Pipeline Blowups of 2016 News Tags biotech Alnylam revusiran Clovis Oncology rociletinib Celldex Therapeutics Rintega Eli Lilly solanezumab Novavax RSV-F Arrowhead ARC-520 ARC-521 ARC-AAT Biomarin drisapersen
Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns Submitted by admin on Thu, 10/06/2016 - 09:24 Read more about Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns Source Marketwatch Headline Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety co… News Tags Alnylam clinical trials revusiran
Alnylam reports results from Phase 2 revusiran trial Submitted by admin on Fri, 11/14/2014 - 09:54 Read more about Alnylam reports results from Phase 2 revusiran trial Source Seeking Alpha Headline Alnylam reports results from Phase 2 revusiran trial News Tags Alnylam revusiran TTR cardiac amyloidosis RNAi